What question did this study set out to answer?

This analysis aims to evaluate trends in minimal residual disease measurement in clinical trials for multiple myeloma from 2014 to 2025.

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

View Full Paper

Ask AI

Bookmark

Authors

A systematic analysis finds rising MRD measurement importance in multiple myeloma trials, suggesting enhanced clinical focus.

This analysis aims to evaluate trends in minimal residual disease measurement in clinical trials for multiple myeloma from 2014 to 2025.
Analyzed clinical trials registered on ClinicalTrials.gov from 2014 to 2025
Included interventional trials or observational studies focusing on therapeutic interventions
Extracted data on therapy response, MRD outcomes, and endpoints classification
Evaluated the percentage of trials incorporating MRD as an outcome
Identified 1336 studies meeting inclusion criteria
MRD inclusion in trials grew from 6.7% in 2014 to 56.8% in 2025
MRD was a primary outcome in 28.4% of trials assessing it
46.0% of recruiting and 46.8% of not yet recruiting trials had an MRD outcome

Choon‐Quinones et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark